SCHEMBL20152048

SCHEMBL20152048

CC1CN(C(C)C)CC1Oc1ccccn1

nearest known ligand 0.42

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
FURIN P09958 1/20 0.42
KDM5A P29375 1/20 0.37
HRH3 Q9Y5N1 2/20 0.36
HCRTR2 O43614 3/20 0.36
HCRTR1 O43613 1/20 0.36
RET P07949 1/20 0.35
PDE3B Q13370 1/20 0.34
PDE3A Q14432 1/20 0.34
PDE10A Q9Y233 1/20 0.34
PDE9A O76083 1/20 0.34
ACACB O00763 1/20 0.33
AVPR1A P37288 1/20 0.33
NAAA Q02083 1/20 0.33
DRD4 P21917 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20147431 0.85 FURIN (0.45) FURINKDM5AHRH3HCRTR2HCRTR1
SCHEMBL20069365 0.82 FURIN (0.43) FURINHCRTR2HCRTR1RETPDE3B
SCHEMBL2737396 0.81 KDM5A (0.45) FURINKDM5AHRH3HCRTR2HCRTR1
SCHEMBL20147447 0.81 FURIN (0.41) FURINKDM5AHCRTR2HCRTR1RET
SCHEMBL20147707 0.77 RET (0.39) FURINKDM5AHRH3HCRTR2HCRTR1
SCHEMBL28668608 0.76 FURIN (0.42) FURINKDM5AHRH3HCRTR2HCRTR1
SCHEMBL20205743 0.76 FURIN (0.39) FURINKDM5AHRH3HCRTR2HCRTR1
SCHEMBL20070271 0.75 DRD4 (0.40) KDM5AHRH3HCRTR2HCRTR1RET
SCHEMBL20147430 0.73 HRH3 (0.52) KDM5AHRH3HCRTR2HCRTR1PDE3B
SCHEMBL19111213 0.73 HRH3 (0.57) KDM5AHRH3PDE3BPDE3APDE10A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11648243-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors ARRAY BIOPHARMA INC. (US) 2023-05-16 US disclosed
US-20200383966-A9 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC (US) 2020-12-10 US disclosed
US-20200030311-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA, INC. 2020-01-30 US disclosed
US-10172845-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors ARRAY BIOPHARMA INC. (US) 2019-01-08 US disclosed
US-20180148445-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2018-05-31 US disclosed
US-20180134703-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2018-05-17 US disclosed
US-20180134703-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2018-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200383966-A9 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, BRAF, RAF1 FURIN 2168/4885KDM5A 902/4885HRH3 1000/4885
US-20180148445-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, BRAF, RAF1 FURIN 2168/4885KDM5A 902/4885HRH3 1000/4885
US-11648243-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors RET, BRAF, RAF1 FURIN 2168/4885KDM5A 902/4885HRH3 1000/4885
US-20200030311-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, BRAF, RAF1 FURIN 2168/4885KDM5A 902/4885HRH3 1000/4885
US-10172845-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors RET, BRAF, RAF1 FURIN 2168/4885KDM5A 902/4885HRH3 1000/4885
US-20180134703-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, BRAF, RAF1 FURIN 2168/4885KDM5A 902/4885HRH3 1000/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.